CAR-engineered T cell therapy has been rapidly developing in recent years. It has achieved impressive curative effects on many types of cancers. However, there are some adverse events following treatment with CAR-T cell therapy. Marked CAR-T cells express not only CARs but also tumor epitopes that can be recognized by an existing monoclonal antibody. If severe adverse effects take place, administration of the specific monoclonal antibody can clear CAR-T cells with no additional off-tumor effects. These monoclonal antibodies are simultaneously able to treat tumors as well. Creative Biolabs provides design and construction services for Marked CAR.
Marked chimeric antigen receptor models and concepts
Nature Reviews Cancer. 2016.
In an animal test, CAR-T cells that express truncated human EGFR polypeptide and retain the intact binding epitope of pharmaceutical-grade anti-EGFR monoclonal antibody (cetuximab), exhibited susceptibility to elimination by cetuximab. The human EGFR polypeptide provides a cell surface marker for in vitro tracking of CAR-T cells through both flow cytometry and immunohistochemistry, and a target for cetuximab mediated antibody-dependent cellular cytotoxicity and in vivo elimination. Another example is that marked CAR-T cells expressing a 136-amino-acid protein that can be recognized by anti-CD34 and anti-CD20 antibodies. This design allows selection with the anti-CD34 monoclonal antibody and it also makes CAR-T cells highly susceptible to lysis by the therapeutic monoclonal rituximab.
With consistent dedications in research and testing, Creative Biolabs has developed many novel CAR constructions that allow the clear of CAR-T cells in time and thus limit the side effects. The great advantage of marked CAR is that it can clear CAR-T cells and alleviate adverse symptoms through administration of a monoclonal antibody.
Copyright © 2007 - 2017 Creative Biolabs. All Rights Reserved